Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trial data
Biotech
Merck’s anti-TL1A secures a ph. 2 hidradenitis suppurativa win
The study met its primary and secondary endpoints at week 16, informing phase 3 development for tulisokibart in HS.
Marissa Russo
Sep 30, 2026 10:20am
Inside the growing world of biopharma prediction markets
Sep 18, 2026 9:39am
Owkin, Servier ink oncology trial and discovery deal
Sep 11, 2026 2:01pm
Teva autoimmune antibody notches ph. 2 win in celiac disease
Sep 2, 2026 10:52am
MoonLake nanobody boosts ph. 3 endpoints in psoriatic arthritis
Aug 10, 2026 11:00am
Double shot of Vistagen’s anxiety nasal spray misses in ph. 2
Aug 6, 2026 10:32am
